Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.

Meanwhile, Bristol Myers Squibb hands back two mystery projects.

Nine years after a groundbreaking deal with Pfizer, Cellectis goes to AstraZeneca for a fresh lease of life.

Assets targeting PSMA and KRAS G12V, plus another gamma-delta Car-T therapy, feature among recently disclosed first-time clinical trial entrants.

But today’s deal with Jiangsu Hengrui doesn’t mean that the group is turning away from an earlier tie-up with Nerviano.

The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data.